Lyell Immunopharma Ownership | Who Owns Lyell Immunopharma?
Lyell Immunopharma Ownership Summary
Lyell Immunopharma is owned by 70.06% institutional investors, 35.44% insiders. Arch venture management is the largest institutional shareholder, holding 19.00% of LYEL shares. Vanguard Total Stock Mkt Idx Inv is the top mutual fund, with 2.30% of its assets in Lyell Immunopharma shares.
LYEL Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Lyell Immunopharma | 70.06% | 35.44% | -5.49% |
| Sector | Healthcare Stocks | 35.49% | 11.78% | 52.72% |
| Industry | Biotech Stocks | 34.84% | 11.71% | 53.45% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Arch venture management | 3.25M | 19.00% | $65.14M |
| Gsk | 1.51M | 8.85% | $30.34M |
| Blackrock | 13.50M | 5.31% | $19.57M |
| Foresite capital management iv | 800.40K | 4.68% | $16.06M |
| Vanguard group | 826.43K | 4.52% | $25.44M |
| Orland properties | 754.70K | 4.42% | $15.14M |
| Almitas capital | 577.81K | 3.38% | $11.59M |
| Wuxi apptec | 7.68M | 3.02% | $11.14M |
| Foresite capital management v | 477.08K | 2.79% | $9.57M |
| Millennium management | 458.90K | 2.68% | $9.21M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Wuxi apptec | 7.68M | 47.74% | $11.14M |
| Arch venture management | 3.25M | 9.62% | $65.14M |
| Foresite capital management iv | 800.40K | 6.77% | $16.06M |
| Orland properties | 754.70K | 5.67% | $15.14M |
| Gsk | 1.51M | 5.06% | $30.34M |
| Foresite capital management v | 477.08K | 3.53% | $9.57M |
| Almitas capital | 577.81K | 2.62% | $11.59M |
| Venbio partners | 337.70K | 2.41% | $6.77M |
| Takeda pharmaceutical | 41.16K | 1.86% | $363.91K |
| Decheng capital | 595.47K | 1.33% | $5.26M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| D. e. shaw | 966.26K | 0.00% | 493.64K |
| Arch venture management | 3.25M | 9.62% | 488.09K |
| Millennium management | 458.90K | 0.00% | 400.25K |
| Wellington management group llp | 367.68K | 0.00% | 367.68K |
| Susquehanna group, llp | 310.20K | 0.00% | 159.18K |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Decheng capital | 595.47K | 1.33% | -11.31M |
| Balyasny asset management | - | - | -1.20M |
| Mwg management | - | - | -1.01M |
| Invenomic capital management lp | - | - | -871.52K |
| Takeda pharmaceutical | 41.16K | 1.86% | -782.15K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Wellington management group llp | 367.68K | 0.00% | 367.68K | $533.13K |
| Velan capital investment management lp | 102.00K | 1.28% | 102.00K | $2.05M |
| Vanguard fiduciary trust | 86.92K | 0.00% | 86.92K | $1.74M |
| Opaleye management | 79.10K | 0.21% | 79.10K | $1.59M |
| Dimensional fund advisors lp | 47.89K | 0.00% | 47.89K | $959.00K |
Sold Out
| Holder | Change |
|---|---|
| Eversource wealth advisors | -1.00 |
| Pnc financial services group | -4.00 |
| True wealth design | -23.00 |
| Nelson, van denburg & campbell wealth management group | -34.00 |
| Daiwa securities group | -45.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 76 | 8.57% | 11,974,545 | 4.99% | 70 | 1.80% | 43 | 34.38% | 9 | -47.06% |
| Dec 31, 2025 | 10 | -82.76% | 864,633 | -91.03% | 4 | 0.11% | 4 | -80.00% | 2 | -89.47% |
| Sep 30, 2025 | 15 | -78.26% | 1,180,540 | -87.25% | 7 | 0.20% | 6 | -50.00% | 4 | -92.86% |
| Jun 30, 2025 | 68 | -39.82% | 9,256,423 | -93.92% | 62 | 939.01% | 12 | -68.42% | 55 | 52.78% |
| Mar 31, 2025 | 112 | 8.74% | 152,309,719 | 1.35% | 51 | 1.50% | 38 | -26.92% | 37 | 48.00% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 537.26K | 2.30% | - |
| iShares Russell 2000 ETF | 4.13M | 1.39% | - |
| T. Rowe Price Health Sciences | 212.18K | 1.10% | -2.38K |
| Biotech Growth Ord | 2.88M | 0.99% | - |
| Vanguard Small Cap Index | 2.24M | 0.87% | 5.37K |
| Vanguard Institutional Extnd Mkt Idx Tr | 162.34K | 0.70% | 3.88K |
| iShares Russell 2000 Value ETF | 1.47M | 0.49% | - |
| Vanguard Small Cap Growth Index Inv | 1.25M | 0.49% | -5.54K |
| Fidelity Small Cap Index | 1.63M | 0.44% | - |
| State St Russell Sm/Mid Cp® Indx NL Cl C | 1.18M | 0.40% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Mar 06, 2026 | ARCH Venture Partners IX, LLC | - | Buy | $12.50M |
| Mar 06, 2026 | ARCH Venture Fund XIII, L.P. | - | Buy | $12.50M |
| Feb 11, 2026 | Seely Lynn | President and CEO | Sell | $174.37K |
| Feb 11, 2026 | Hill Stephen J. | Chief Operating Officer | Sell | $28.91K |
| Feb 11, 2026 | Lee Gary K. | Chief Scientific Officer | Sell | $39.08K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q1 | - | 7 |
| 2025 Q4 | - | 6 |
| 2025 Q3 | - | 12 |
| 2025 Q2 | - | - |
| 2025 Q1 | 5 | - |
LYEL Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools